ARTICLE | Company News

ODAC dates for Novartis' panobinostat, Rockwell's Triferic

October 9, 2014 2:20 AM UTC

FDA's Oncologic Drugs Advisory Committee will meet on Nov. 6 to discuss NDAs for panobinostat ( LBH589) from Novartis AG (NYSE:NVS; SIX:NOVN) and Triferic soluble ferric pyrophosphate citrate from Rockwell Medical Inc. (NASDAQ:RMTI).

Panobinostat, an oral pan-deacetylase (DAC) inhibitor, is under Priority Review in combination with Velcade bortezomib from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and dexamethasone to treat patients with multiple myeloma who have received at least one prior therapy. ...